CRISPR Therapeutics Presents Positive Data on Allogeneic …NasdaqOff-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors-. -New data demonstrate high editing.and more »… Continue reading
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018GlobeNewswire (press release)ZUG, Switzerland and CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharma… Continue reading
Baylor College of Medicine News (press release)New gene therapy shows promise in reversing vision loss or blindness in patients with rare diseaseBaylor College of Medicine News (press release)A new FDA-approved gene therapy treatment for patients with … Continue reading
Fortune |
Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer
Fortune New study results released Monday continue to cement drug giant Merck’s status as the force to be reckoned with in the lung cancer treatment space. Merck’s flagship cancer immunotherapy Keytruda (or pembrolizumab), combined with chemotherapy, helped … Merck BMS Roche lung cancer immunotherapy data – Business InsiderBusiness Insider Merck lung cancer trial boosts immunotherapy hopes – Financial TimesFinancial Times Merck, Bristol-Myers immunotherapies impress in key lung cancer …Reuters WHTC –Zacks all 76 news articles » |
Scope (blog) |
Altered immune cells clear childhood brain tumor in mice
Science Daily To begin the research, the scientists screened human DIPG tumor cultures for surface molecules that could act as targets for CAR–T cells. In CAR-T therapies now used in humans, some of the patient’s own immune cells are removed, engineered to attack a … Engineered immune cells clear deadly pediatric brain tumor in miceScope (blog) |
Fred Hutch News Service |
Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal
Fred Hutch News Service Solid tumors like breast and lung cancer, by their nature, construct all kinds of barriers to an effective immunotherapy. Dr. Kristin Anderson, a researcher at Fred Hutchinson Cancer Research Center who works on a type of immunotherapy known as T-cell … |
Fred Hutch News Service |
Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal
Fred Hutch News Service Solid tumors like breast and lung cancer, by their nature, construct all kinds of barriers to an effective immunotherapy. Dr. Kristin Anderson, a researcher at Fred Hutchinson Cancer Research Center who works on a type of immunotherapy known as T-cell … Boosting T cell ‘memory’ may result in longer-lasting and effective responses for patientsMedical Xpress |